Ensysce Biosciences (ENSC) Cash & Equivalents Growth (3y) (2020 - 2025)
Ensysce Biosciences (ENSC) Cash & Equivalents Growth (3y) (2020 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -23.18% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 14.34% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.45% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.22% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.85% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -27.97% |
| 10 | Ensysce Biosciences | 942,649.19 | -3.37 Mn | - | 11.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.05% |
| Sep 30, 2025 | -28.11% |
| Jun 30, 2025 | -43.23% |
| Mar 31, 2025 | -28.76% |
| Dec 31, 2024 | -34.15% |
| Sep 30, 2024 | -15.34% |
| Jun 30, 2024 | -49.31% |
| Mar 31, 2024 | 138.80% |
| Dec 31, 2023 | 79.52% |
| Sep 30, 2023 | 201.39% |
| Jun 30, 2023 | 148.35% |
| Mar 31, 2023 | 103.52% |
| Dec 31, 2022 | 43.68% |
| Sep 30, 2022 | 52.33% |
| Jun 30, 2022 | 105.06% |
| Mar 31, 2022 | 77.61% |
| Dec 31, 2021 | 94.83% |
| Sep 30, 2021 | 57.44% |
| Jun 30, 2021 | 66.93% |
| Mar 31, 2021 | -49.16% |